Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks - Viatris (NASDAQ:VTRS

Viatris Inc's (NASDAQ:VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.

The Company cited the risk of the label is missing on some prefilled pens contained inside labeled cartons of the drug.
The recall doesn't cover Viatris' recently launched interchangeable Semglee biosimilars, which come in branded and unbranded formats.
The lot in question was produced by Biocon and distributed by Mylan in the U.S. between May 11, 2021, and Nov. 11, 2021.
According to the release, the batch, which contains cartons of five 3-ml prefilled Semglee pens, was due to expire in August 2022.
Viatris did not say how many five-pen cartons were in the lot.
The labeling glitch could pose problems for patients who use both long- and short-acting insulin to manage their diabetes, Viatris warned.
Patients could accidentally take the wrong insulin, which could hamper glycemic control, resulting in serious health risks.
As of Wednesday, Viatris had not received any safety reports linked to the recall.
Price Action: VTRS shares are up 0.28% at $14.76 during the market session on the last check Thursday.

To add Benzinga News as your preferred source on Google, click here.